Nigrostriatal function in humans studied with positron emission tomography

Ann Neurol. 1989 Oct;26(4):535-42. doi: 10.1002/ana.410260407.

Abstract

The dopamine depletion that is characteristic of Parkinson's disease has been hypothesized to result from the combination of environmentally induced subclinical damage to the substantia nigra and the age-related loss of additional nigral neurons. Essential to this hypothesis is the existence of deteriorating function in the nigrostriatal pathway with advancing age. The present study was undertaken with [18F]6-fluoro-L-dopa and positron emission tomography to determine in vivo the effects of age on the nigrostriatal pathway in a series of 10 asymptomatic subjects (age range, 22-80 years; mean, 49.8 years). A graphical approach was used in the analysis of multiple-time tracer-uptake data to establish the presence of a compartment with unidirectional uptake and to calculate the rate constant, K, for uptake of [18F]6-fluoro-L-dopa from blood to striatum during steady-state, an index of the functional integrity of nigrostriatal nerve endings. There was a significant linear relationship between K and age (r = 0.80, p less than 0.005) with a decrease of 53.3% over the age range studied. These results demonstrate the application of a unidirectional transfer model to the analysis of [18F]6-fluoro-L-dopa and positron emission tomography data and provide in vivo confirmation of an age-related impairment of nigrostriatal function.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Aging / metabolism*
  • Corpus Striatum / diagnostic imaging
  • Corpus Striatum / metabolism*
  • Corpus Striatum / physiology
  • Dihydroxyphenylalanine / analogs & derivatives*
  • Dihydroxyphenylalanine / pharmacokinetics
  • Female
  • Humans
  • Male
  • Middle Aged
  • Substantia Nigra / diagnostic imaging
  • Substantia Nigra / metabolism*
  • Substantia Nigra / physiology
  • Tomography, Emission-Computed*

Substances

  • fluorodopa F 18
  • Dihydroxyphenylalanine